Statement: the secondary trial recorded more total occurences of gastrointestinal adverse events than the primary trial.
Primary_evidence: Adverse Events 1:   Total: 23/120 (19.17%)   Febrile neutropenia 4/120 (3.33%)   Leukopenia 2/120 (1.67%)   Neutropenia 8/120 (6.67%)   Cardiac tamponade 0/120 (0.00%)   Ventricular arrhythmia 1/120 (0.83%)   Ascites 0/120 (0.00%)   Oesophagitis 0/120 (0.00%)   Large intestine polyp 0/120 (0.00%)   Death 1/120 (0.83%)   Liver injury 1/120 (0.83%)   Pneumonia 3/120 (2.50%) Adverse Events 2:   Total: 30/122 (24.59%)   Febrile neutropenia 3/122 (2.46%)   Leukopenia 3/122 (2.46%)   Neutropenia 9/122 (7.38%)   Cardiac tamponade 2/122 (1.64%)   Ventricular arrhythmia 0/122 (0.00%)   Ascites 1/122 (0.82%)   Oesophagitis 1/122 (0.82%)   Large intestine polyp 0/122 (0.00%)   Death 1/122 (0.82%)   Liver injury 0/122 (0.00%)   Pneumonia 5/122 (4.10%)
Secondary_evidence: Adverse Events 1:   Total: 47/254 (18.50%)   Anaemia 1/254 (0.39%)   Febrile neutropenia 1/254 (0.39%)   Lymphadenopathy 1/254 (0.39%)   Acute myocardial infarction 1/254 (0.39%)   Angina pectoris 0/254 (0.00%)   Angina unstable 0/254 (0.00%)   Bundle branch block left 0/254 (0.00%)   Cardiac failure 4/254 (1.57%)   Coronary artery disease 0/254 (0.00%)   Coronary artery stenosis 1/254 (0.39%) Adverse Events 2:   Total: 56/269 (20.82%)   Anaemia 1/269 (0.37%)   Febrile neutropenia 0/269 (0.00%)   Lymphadenopathy 0/269 (0.00%)   Acute myocardial infarction 0/269 (0.00%)   Angina pectoris 3/269 (1.12%)   Angina unstable 1/269 (0.37%)   Bundle branch block left 1/269 (0.37%)   Cardiac failure 1/269 (0.37%)   Coronary artery disease 1/269 (0.37%)   Coronary artery stenosis 0/269 (0.00%)